
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is a promising company with a strong focus on developing targeted radiopharmaceuticals for solid tumor cancers, particularly through its AKY-1189 and AKY-2519 pipeline products. With recent acquisitions and positive trial results for its drugs, the company is poised for success in the growing market for radiopharmaceutical treatments. The company's strong focus on targeting specific proteins found in various cancers sets it apart from other competitors in the space.
Bears say
Aktis Oncology is facing intense competition and has a CEO with limited industry experience, as well as a COO who has only been in her position since 2022. In addition, the company's pipeline products are still in the early stages of development, with no current revenues and limited data to support their efficacy. With a highly competitive landscape and lack of financial stability, Aktis Oncology's stock is likely to underperform in the short-term.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares